Ascelia Pharma

AGM Information • Apr 13, 2021

13 April 2021 11:30:00 CEST

Bulletin from the extraordinary general meeting in Ascelia Pharma AB

Today, on 13 April 2021, an extraordinary general meeting was held in Ascelia Pharma AB. A sum-mary of the adopted resolutions follows below. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the meeting was held only by advance voting (postal vote) in accordance with temporary legislation.

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Resolution on approval of the board of directors' resolution on directed issue of shares The meeting resolved to approve the board of directors' resolution of 17 March 2021 to increase the company's share capital with not more than SEK 5,000,000 through the issue of not more than 5,000,000 ordinary shares. Through the directed issue of shares, the company will receive SEK 200 million before transaction costs. The net proceeds are intended to be used for (i) financing the Phase 2 study for the oral chemotherapy drug candidate Oncoral, (ii) accelerating activities towards the commercialization of the diagnostic drug Mangoral, currently in an ongoing Phase III study and (iii) general corporate purposes.

About Us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Mangoral and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.

About Mangoral

Mangoral (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Mangoral, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study.

About Oncoral

Oncoral is a novel irinotecan chemotherapy tablet developed initially for the treatment of gastric cancer. Irinotecan chemotherapy has an established potent anti-tumor effect. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following successful Phase 1 results, Oncoral is now prepared for Phase 2 clinical development.

Attachments

Bulletin from the extraordinary general meeting in Ascelia Pharma AB